NASH Drug Development: Seeing the Light at the End of the Tunnel?

Nonalcoholic steatohepatitis (NASH) is a chronic liver disease affecting a large population worldwide. No clinically approved drugs are available. In this minireview, we discuss the heterogeneous nature of NASH and lack of consensus in outcome measures among clinical trials. We summarize NASH therap...

Descripción completa

Detalles Bibliográficos
Autor principal: Chen, Yong Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2023
Materias:
Mini Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500295/
https://www.ncbi.nlm.nih.gov/pubmed/37719961
http://dx.doi.org/10.14218/JCTH.2023.00058
_version_ 1785105890806857728
author Chen, Yong Q.
author_facet Chen, Yong Q.
author_sort Chen, Yong Q.
collection PubMed
description Nonalcoholic steatohepatitis (NASH) is a chronic liver disease affecting a large population worldwide. No clinically approved drugs are available. In this minireview, we discuss the heterogeneous nature of NASH and lack of consensus in outcome measures among clinical trials. We summarize NASH therapeutic targets and candidate drugs. We compare the efficacy of 33 published clinical trials that evaluated noninvasive biomarkers and liver biopsy. Currently, phase II trial results of fibroblast growth factor 21 (FGF21) and phase III trial results of resmetirom and pioglitazone are encouraging.
format Online
Article
Text
id pubmed-10500295
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher XIA & HE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-105002952023-09-15 NASH Drug Development: Seeing the Light at the End of the Tunnel? Chen, Yong Q. J Clin Transl Hepatol Mini Review Nonalcoholic steatohepatitis (NASH) is a chronic liver disease affecting a large population worldwide. No clinically approved drugs are available. In this minireview, we discuss the heterogeneous nature of NASH and lack of consensus in outcome measures among clinical trials. We summarize NASH therapeutic targets and candidate drugs. We compare the efficacy of 33 published clinical trials that evaluated noninvasive biomarkers and liver biopsy. Currently, phase II trial results of fibroblast growth factor 21 (FGF21) and phase III trial results of resmetirom and pioglitazone are encouraging. XIA & HE Publishing Inc. 2023-11-28 2023-06-05 /pmc/articles/PMC10500295/ /pubmed/37719961 http://dx.doi.org/10.14218/JCTH.2023.00058 Text en © 2023 Authors. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Mini Review
Chen, Yong Q.
NASH Drug Development: Seeing the Light at the End of the Tunnel?
title NASH Drug Development: Seeing the Light at the End of the Tunnel?
title_full NASH Drug Development: Seeing the Light at the End of the Tunnel?
title_fullStr NASH Drug Development: Seeing the Light at the End of the Tunnel?
title_full_unstemmed NASH Drug Development: Seeing the Light at the End of the Tunnel?
title_short NASH Drug Development: Seeing the Light at the End of the Tunnel?
title_sort nash drug development: seeing the light at the end of the tunnel?
topic Mini Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10500295/
https://www.ncbi.nlm.nih.gov/pubmed/37719961
http://dx.doi.org/10.14218/JCTH.2023.00058
work_keys_str_mv AT chenyongq nashdrugdevelopmentseeingthelightattheendofthetunnel

Ejemplares similares